Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Europe and North America. The aim of the trial is to assess
disease activity and safety in subjects with moderately to severely active Crohn's disease
(CD) when treated with NNC 0142-0000-0002.